Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 18/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 15/20 | 0.53 |
| ▸ | ABL1 | P00519 | 10/20 | 0.53 |
| ▸ | BCR | P11274 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325101 | 0.92 | DDR2 (0.53) | DDR2DDR1ABL1BCRKIT | |
| SCHEMBL18775257 | 0.91 | DDR2 (0.51) | DDR2DDR1ABL1BCRKIT | |
| SCHEMBL17325057 | 0.87 | ABL1 (0.46) | DDR2ABL1BCRKIT | |
| SCHEMBL18762351 | 0.86 | ABL1 (0.64) | ABL1KITRET | |
| SCHEMBL17325094 | 0.86 | ABL1 (0.64) | ABL1KITRET | |
| SCHEMBL17316213 | 0.85 | DDR1 (0.69) | DDR2DDR1ABL1BCRKIT | |
| SCHEMBL18775252 | 0.85 | ABL1 (0.44) | DDR2ABL1BCRKIT | |
| SCHEMBL17325095 | 0.85 | RET (0.62) | ABL1KITRET | |
| SCHEMBL18775259 | 0.84 | ABL1 (0.45) | DDR2DDR1ABL1BCRKIT | |
| SCHEMBL18775244 | 0.84 | ABL1 (0.52) | ABL1KITRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | DDR2 951/4885DDR1 890/4885ABL1 1/4885 |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, ABL2 | DDR2 1023/4885DDR1 1096/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.